Abstracts tagged "low back pain and osteoarthritis"

Abstract Number: 2850 • 2017 ACR/ARHP Annual Meeting
Jakinibs Decrease Chronic Low Back Pain and Increase Function: A Proof of Concept Trial
Maria Greenwald¹ and JoAnn Ball², ¹Desert Medical Advances, Palm Desert, CA, ²rheumatology, Desert Medical Advances, Palm Deseret, CA
Background/Purpose: Low back pain (LBP) is ubiquitous and estimated to affect 26% of Americans in any 3 month period. Why would rheumatoid arthritis patients be…
Abstract Number: 2121 • 2016 ACR/ARHP Annual Meeting
Identification of microRNA-181a-5p and microRNA-4454 As Mediators of Facet Cartilage Degeneration
Akihiro Nakamura^1,2, Y. Raja Rampersaud^3,4, Anirudh Sharma^1,2, Stephen J. Lewis^3,5, Brian Wu^1,2, Poulami Datta^1,2, Kala Sundararajan⁶, Helal Endisha^1,2, Evgeny Rossomacha^1,2, Jason S Rockel^1,2, Igor Jurisica⁷ and Mohit kapoor^1,2,8, ¹Genetics and Development, Krembil Research Institute, University Health Network, Toronto, ON, Canada, ²Arthritis Program, University Health Netwok, Toronto, ON, Canada, ³Orthopaedic Surgery and Neurosurgery, Arthritis Program, University Health Network, Toronto, ON, Canada, ⁴Orthopaedics, Toronto Western Hospital, Toronto, ON, Canada, ⁵Spinal Program, Krembil Neuroscience Centre, Toronto Western Hospital, Toronto, ON, Canada, ⁶Orthopaedic Research Department, Toronto Western Hospital, University Health Network, Toronto, ON, Canada, ⁷Medical Biophysics and Computer Science, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada, ⁸Surgery, Laboratory Medicine, and Pathobiology, University of Toronto, Toronto, ON, Canada
Background/Purpose: Osteoarthritis (OA) of spine (facet joints, FJ) is one of the major causes of severe low back pain and disability worldwide. However, specific mechanisms…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].